ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Insights, Forecast to 2030
Published Date: December 2024
|
Report Code: QYRE-Auto-17Q5991
Home | Market Reports | Health| Nursing
Global Non Alcoholic Steatohepatitis NASH Treatment Market Insights and Forecast to 2028
BUY CHAPTERS

Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Insights, Forecast to 2030

Code: QYRE-Auto-17Q5991
Report
December 2024
Pages:93
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Allergan Plc (Tobira)
Bristol–Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
Zydus Cadila

Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Non-Alcoholic Steatohepatitis (NASH) Treatment Market

Non-Alcoholic Steatohepatitis (NASH) Treatment Market

Market Analysis and Insights: Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market
The global Non-Alcoholic Steatohepatitis (NASH) Treatment market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Non-Alcoholic Steatohepatitis (NASH) Treatment market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Non-Alcoholic Steatohepatitis (NASH) Treatment, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Non-Alcoholic Steatohepatitis (NASH) Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Non-Alcoholic Steatohepatitis (NASH) Treatment revenue, market share and industry ranking of main companies, data from 2019 to 2024. Identification of the major stakeholders in the global Non-Alcoholic Steatohepatitis (NASH) Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Non-Alcoholic Steatohepatitis (NASH) Treatment revenue, projected growth trends, production technology, application and end-user industry.
Market Segmentation

Scope of Non-Alcoholic Steatohepatitis (NASH) Treatment Market Report

Report Metric Details
Report Name Non-Alcoholic Steatohepatitis (NASH) Treatment Market
CAGR 5%
Segment by Type
  • Off-Label
  • Therapeutic
Segment by Application
  • Hospital Pharmacy
  • Online Provider
  • Retail Pharmacy
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Allergan Plc (Tobira), Bristol Myers Squibb, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Zydus Cadila
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Revenue of Non-Alcoholic Steatohepatitis (NASH) Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Non-Alcoholic Steatohepatitis (NASH) Treatment companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: North America (US & Canada) by Type, by Application and by country, revenue for each segment.
  • Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
  • Chapter 8: China by Type, and by Application, revenue for each segment.
  • Chapter 9: Asia (excluding China) by Type, by Application and by region, revenue for each segment.
  • Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, revenue for each segment.
  • Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-Alcoholic Steatohepatitis (NASH) Treatment revenue, gross margin, and recent development, etc.
  • Chapter 12: Analyst's Viewpoints/Conclusions

FAQ for this report

Who are the main players in the Non-Alcoholic Steatohepatitis (NASH) Treatment Market report?

Ans: The main players in the Non-Alcoholic Steatohepatitis (NASH) Treatment Market are Allergan Plc (Tobira), Bristol Myers Squibb, Galmed Pharmaceuticals, Genfit SA, Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Zydus Cadila

What are the Application segmentation covered in the Non-Alcoholic Steatohepatitis (NASH) Treatment Market report?

Ans: The Applications covered in the Non-Alcoholic Steatohepatitis (NASH) Treatment Market report are Hospital Pharmacy, Online Provider, Retail Pharmacy

What are the Type segmentation covered in the Non-Alcoholic Steatohepatitis (NASH) Treatment Market report?

Ans: The Types covered in the Non-Alcoholic Steatohepatitis (NASH) Treatment Market report are Off-Label, Therapeutic

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030
1.2.2 Off-Label
1.2.3 Therapeutic
1.3 Market by Application
1.3.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Online Provider
1.3.4 Retail Pharmacy
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Perspective (2019-2030)
2.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Trends by Region
2.2.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Region (2019-2024)
2.2.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Region (2025-2030)
2.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Dynamics
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Trends
2.3.2 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers
2.3.3 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Challenges
2.3.4 Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Non-Alcoholic Steatohepatitis (NASH) Treatment by Players
3.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Players (2019-2024)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment, Ranking by Revenue, 2022 VS 2023 VS 2024
3.4 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Concentration Ratio
3.4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2023
3.5 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment Head office and Area Served
3.6 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment, Product and Application
3.7 Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Alcoholic Steatohepatitis (NASH) Treatment Breakdown Data by Type
4.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Type (2019-2024)
4.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Type (2025-2030)
5 Non-Alcoholic Steatohepatitis (NASH) Treatment Breakdown Data by Application
5.1 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Historic Market Size by Application (2019-2024)
5.2 Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2019-2030)
6.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
6.2.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024)
6.2.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030)
6.2.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
6.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
6.3.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024)
6.3.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030)
6.3.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
6.4 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
6.4.1 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country: 2019 VS 2023 VS 2030
6.4.2 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2019-2024)
6.4.3 North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2025-2030)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2019-2030)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
7.2.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024)
7.2.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030)
7.2.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
7.3.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024)
7.3.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030)
7.3.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
7.4 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
7.4.1 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country: 2019 VS 2023 VS 2030
7.4.2 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2019-2024)
7.4.3 Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2025-2030)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2019-2030)
8.2 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
8.2.1 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024)
8.2.2 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030)
8.2.3 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
8.3 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
8.3.1 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024)
8.3.2 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030)
8.3.3 China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
9 Asia (excluding China)
9.1 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2019-2030)
9.2 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
9.2.1 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024)
9.2.2 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030)
9.2.3 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
9.3 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
9.3.1 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024)
9.3.2 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030)
9.3.3 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
9.4 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region
9.4.1 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region: 2019 VS 2023 VS 2030
9.4.2 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2019-2024)
9.4.3 Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2025-2030)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (2019-2030)
10.2 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024)
10.2.2 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030)
10.2.3 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
10.3 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024)
10.3.2 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030)
10.3.3 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
10.4 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country: 2019 VS 2023 VS 2030
10.4.2 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2019-2024)
10.4.3 Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2025-2030)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Allergan Plc (Tobira)
11.1.1 Allergan Plc (Tobira) Company Details
11.1.2 Allergan Plc (Tobira) Business Overview
11.1.3 Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.1.4 Allergan Plc (Tobira) Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.1.5 Allergan Plc (Tobira) Recent Developments
11.2 Bristol Myers Squibb
11.2.1 Bristol Myers Squibb Company Details
11.2.2 Bristol Myers Squibb Business Overview
11.2.3 Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.2.4 Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.2.5 Bristol Myers Squibb Recent Developments
11.3 Galmed Pharmaceuticals
11.3.1 Galmed Pharmaceuticals Company Details
11.3.2 Galmed Pharmaceuticals Business Overview
11.3.3 Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.3.4 Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.3.5 Galmed Pharmaceuticals Recent Developments
11.4 Genfit SA
11.4.1 Genfit SA Company Details
11.4.2 Genfit SA Business Overview
11.4.3 Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.4.4 Genfit SA Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.4.5 Genfit SA Recent Developments
11.5 Gilead Sciences, Inc.
11.5.1 Gilead Sciences, Inc. Company Details
11.5.2 Gilead Sciences, Inc. Business Overview
11.5.3 Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.5.4 Gilead Sciences, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.5.5 Gilead Sciences, Inc. Recent Developments
11.6 Intercept Pharmaceuticals, Inc.
11.6.1 Intercept Pharmaceuticals, Inc. Company Details
11.6.2 Intercept Pharmaceuticals, Inc. Business Overview
11.6.3 Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.6.4 Intercept Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.6.5 Intercept Pharmaceuticals, Inc. Recent Developments
11.7 Zydus Cadila
11.7.1 Zydus Cadila Company Details
11.7.2 Zydus Cadila Business Overview
11.7.3 Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Introduction
11.7.4 Zydus Cadila Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
11.7.5 Zydus Cadila Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
FEATURED COMPANIES
Allergan Plc (Tobira)
Bristol–Myers Squibb
Galmed Pharmaceuticals
Genfit SA
Gilead Sciences Inc
Intercept Pharmaceuticals Inc
Zydus Cadila
List of Tables
    Table 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type (US$ Million), 2019 VS 2023 VS 2030
    Table 2. Key Players of Off-Label
    Table 3. Key Players of Therapeutic
    Table 4. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Application (US$ Million), 2019 VS 2023 VS 2030
    Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 7. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region (2019-2024)
    Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Region (2025-2030) & (US$ Million)
    Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region (2025-2030)
    Table 10. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Trends
    Table 11. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Drivers
    Table 12. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Challenges
    Table 13. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Restraints
    Table 14. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue by Players (2019-2024) & (US$ Million)
    Table 15. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Players (2019-2024)
    Table 16. Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment as of 2023)
    Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Industry Ranking 2022 VS 2023 VS 2024
    Table 18. Global 5 Largest Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue (CR5 and HHI) & (2019-2024)
    Table 19. Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment, Headquarters and Area Served
    Table 20. Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment, Product and Application
    Table 21. Global Key Players of Non-Alcoholic Steatohepatitis (NASH) Treatment, Product and Application
    Table 22. Mergers & Acquisitions, Expansion Plans
    Table 23. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 24. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2019-2024)
    Table 25. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Type (2025-2030) & (US$ Million)
    Table 26. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Market Share by Type (2025-2030)
    Table 27. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 28. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Application (2019-2024)
    Table 29. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Forecasted Market Size by Application (2025-2030) & (US$ Million)
    Table 30. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue Share by Application (2025-2030)
    Table 31. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 32. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 33. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 34. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 35. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 36. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 37. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 38. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 39. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 40. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 41. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 42. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 43. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 44. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 45. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 46. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 47. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 48. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 49. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 50. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 51. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 52. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 53. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Rate (CAGR) by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 54. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2019-2024) & (US$ Million)
    Table 55. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Region (2025-2030) & (US$ Million)
    Table 56. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2019-2024) & (US$ Million)
    Table 57. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Type (2025-2030) & (US$ Million)
    Table 58. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2019-2024) & (US$ Million)
    Table 59. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Application (2025-2030) & (US$ Million)
    Table 60. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Growth Rate (CAGR) by Country (US$ Million): 2019 VS 2023 VS 2030
    Table 61. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2019-2024) & (US$ Million)
    Table 62. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size by Country (2025-2030) & (US$ Million)
    Table 63. Allergan Plc (Tobira) Company Details
    Table 64. Allergan Plc (Tobira) Business Overview
    Table 65. Allergan Plc (Tobira) Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 66. Allergan Plc (Tobira) Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 67. Allergan Plc (Tobira) Recent Developments
    Table 68. Bristol Myers Squibb Company Details
    Table 69. Bristol Myers Squibb Business Overview
    Table 70. Bristol Myers Squibb Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 71. Bristol Myers Squibb Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 72. Bristol Myers Squibb Recent Developments
    Table 73. Galmed Pharmaceuticals Company Details
    Table 74. Galmed Pharmaceuticals Business Overview
    Table 75. Galmed Pharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 76. Galmed Pharmaceuticals Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 77. Galmed Pharmaceuticals Recent Developments
    Table 78. Genfit SA Company Details
    Table 79. Genfit SA Business Overview
    Table 80. Genfit SA Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 81. Genfit SA Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 82. Genfit SA Recent Developments
    Table 83. Gilead Sciences, Inc. Company Details
    Table 84. Gilead Sciences, Inc. Business Overview
    Table 85. Gilead Sciences, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 86. Gilead Sciences, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 87. Gilead Sciences, Inc. Recent Developments
    Table 88. Intercept Pharmaceuticals, Inc. Company Details
    Table 89. Intercept Pharmaceuticals, Inc. Business Overview
    Table 90. Intercept Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 91. Intercept Pharmaceuticals, Inc. Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 92. Intercept Pharmaceuticals, Inc. Recent Developments
    Table 93. Zydus Cadila Company Details
    Table 94. Zydus Cadila Business Overview
    Table 95. Zydus Cadila Non-Alcoholic Steatohepatitis (NASH) Treatment Product
    Table 96. Zydus Cadila Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024) & (US$ Million)
    Table 97. Zydus Cadila Recent Developments
    Table 98. Research Programs/Design for This Report
    Table 99. Key Data Information from Secondary Sources
    Table 100. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 2. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type: 2023 VS 2030
    Figure 3. Off-Label Features
    Figure 4. Therapeutic Features
    Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application: 2023 VS 2030
    Figure 7. Hospital Pharmacy Case Studies
    Figure 8. Online Provider Case Studies
    Figure 9. Retail Pharmacy Case Studies
    Figure 10. Non-Alcoholic Steatohepatitis (NASH) Treatment Report Years Considered
    Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size (US$ Million), Year-over-Year: 2019-2030
    Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region: 2023 VS 2030
    Figure 14. Global Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Players in 2023
    Figure 15. Global Top Non-Alcoholic Steatohepatitis (NASH) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Alcoholic Steatohepatitis (NASH) Treatment as of 2023)
    Figure 16. The Top 10 and 5 Players Market Share by Non-Alcoholic Steatohepatitis (NASH) Treatment Revenue in 2023
    Figure 17. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 18. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
    Figure 19. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
    Figure 20. North America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2019-2030)
    Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 23. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 24. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
    Figure 25. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
    Figure 26. Europe Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2019-2030)
    Figure 27. Germany Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 28. France Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 29. U.K. Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 30. Italy Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 31. Russia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 32. Nordic Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 33. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 34. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
    Figure 35. China Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
    Figure 36. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 37. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
    Figure 38. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
    Figure 39. Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Region (2019-2030)
    Figure 40. Japan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 41. South Korea Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 42. China Taiwan Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 43. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 44. India Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 45. Australia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 46. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY (2019-2030) & (US$ Million)
    Figure 47. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Type (2019-2030)
    Figure 48. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Application (2019-2030)
    Figure 49. Middle East, Africa, and Latin America Non-Alcoholic Steatohepatitis (NASH) Treatment Market Share by Country (2019-2030)
    Figure 50. Brazil Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 51. Mexico Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 52. Turkey Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 54. Israel Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 55. GCC Countries Non-Alcoholic Steatohepatitis (NASH) Treatment Market Size YoY Growth (2019-2030) & (US$ Million)
    Figure 56. Allergan Plc (Tobira) Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 57. Bristol Myers Squibb Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 58. Galmed Pharmaceuticals Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 59. Genfit SA Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 60. Gilead Sciences, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 61. Intercept Pharmaceuticals, Inc. Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 62. Zydus Cadila Revenue Growth Rate in Non-Alcoholic Steatohepatitis (NASH) Treatment Business (2019-2024)
    Figure 63. Bottom-up and Top-down Approaches for This Report
    Figure 64. Data Triangulation
    Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Nano String

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Molecular Quality Controls Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-4P1358
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Ozone Therapy in Dermatology Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-1O14324
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Ankle Replacement System Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-36H5857
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Global Pharyngeal Cancer Therapeutics Market Insights, Forecast to 2030

120 Pages
Type: Report
Code: QYRE-Auto-9E14435
Fri Dec 27 00:00:00 UTC 2024

Add to Cart

Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions